Zacks Research Issues Negative Forecast for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research reduced their Q3 2025 earnings estimates for Esperion Therapeutics in a research report issued on Wednesday, February 12th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn ($0.02) per share for the quarter, down from their previous estimate of ($0.01). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.00 EPS and FY2026 earnings at ($0.28) EPS.

Other equities analysts have also issued research reports about the stock. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Stock Performance

Shares of ESPR stock opened at $1.87 on Monday. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94. The company has a 50 day moving average price of $2.14 and a 200 day moving average price of $2.11. The firm has a market capitalization of $368.46 million, a price-to-earnings ratio of -2.92 and a beta of 1.01.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ESPR. The Manufacturers Life Insurance Company purchased a new position in shares of Esperion Therapeutics in the second quarter valued at $159,000. SG Americas Securities LLC boosted its stake in shares of Esperion Therapeutics by 105.9% in the third quarter. SG Americas Securities LLC now owns 77,049 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 39,635 shares during the period. Traphagen Investment Advisors LLC purchased a new position in shares of Esperion Therapeutics in the third quarter valued at $27,000. Versor Investments LP purchased a new position in shares of Esperion Therapeutics in the third quarter valued at $44,000. Finally, Summit Wealth Group LLC purchased a new position in shares of Esperion Therapeutics in the third quarter valued at $66,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.